Trial Profile
A single arm, two center, phase II study of RAD001 [everolimus] in patients with metastatic, hormone-refractory prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 15 May 2012 Actual patient number is 47 according to ClinicalTrials.gov.
- 15 May 2012 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.